WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (Nasdaq:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced that John V. Oyler, Founder, Chief Executive Officer, and Chairman, and Howard Liang, Ph.D., Chief Financial Officer and Chief Strategy Officer, will present at the 25th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona. The presentation is scheduled for 3:00PM MST on November 7, 2016.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Lucy Li, Ph.D.
Source: BeiGene, LTD.